J Med Cases

Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc

Journal website https://www.journalmc.org

Case Report

Volume 12, Number 12, December 2021, pages 503-510

Male Adenoid Cystic Carcinoma of the Breast

Figure 1. Breast adenoid cystic carcinoma ultrasound and postoperative findings. (a) Ultrasonography revealed a well-defined oval hypoechoic mass in the retroareolar region of the left breast. (b) The subareolar mass progressively enlarged over the course of 2 years. (c) Ultrasonography showed a hypoechoic area after lumpectomy. (d) Ultrasonography of an enlarged axillary lymph node with a clear boundary.

Figure 2. Microscopic pathology of breast adenoid cystic carcinoma. (a) H&E staining showing an cribriform growth pattern. (b) H&E staining showing tubular and solid growth patterns. (c) IHC staining for CD117. (d) IHC staining for P63. H&E: hematoxylin and eosin stain; IHC: immunohistochemistry.

Figure 3. Whole-body evaluation by ¹⁸F-FDG PET/CT. The ¹⁸F-FDG PET/CT MIP (a) shows uptake (SUVmax 2.5) in the left breast lesion (b and d, red arrows), with a disordered tissue structure (c, red arrow). Small lymph nodes were found in the bilateral neck and bilateral axillary regions (e-g, red arrows, SUVmax 1.65). ¹⁸F-FDG PET/CT: ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography; MIP: maximum intensity projection; SUVmax: maximum standardized uptake value.

**Table 1.** Summary of Male Adenoid Cystic Carcinoma of Breast
References	Year	Age	Diameter	Node	Surgery	Adjuvant treatment	Outcome of follow up
Neg: negative; Pos: positive; NR: no report; LM: lumpectomy; MRM: modified radical mastectomy; ALND: axillary lymph node dissection; ScM: subcutaneous mastectomy; SM: simple mastectomy; SNB: sentinel node biopsy; RM: radical mastectomy.
Presenting case	2021	23	1.3 cm	Neg	LM → MRM + ALND	None	Remain well after 24 months of follow-up
Hogan and Fan [20]	2020	60	2.1 cm	NR	LM	Radiotherapy	Lung metastasis
Pang et al [19]	2019	44	1.2 cm	Neg	LM → MRM + ALND	Postoperative chemotherapy	Remain well after 26 months of follow-up
Douglas and Mackenzie [18]	2019	21	5.0 cm	Neg	ScM → SM + SNB	None	Remain well after 12 months of follow-up
Zadeh et al [17]	2017	42	4.0 cm	Neg	MRM + ALND	None	Remain well after 12 months of follow-up
Tang et al [16]	2015	19	3.0 cm	Neg	RM + ALND	Endocrine therapy	Remain well after 67 months of follow-up
Yoo et al [15]	2013	41	1.7 cm	Pos	NR	None	Bone and lung metastasis
Sahan et al [14]	2012	60	1.3 cm	NR	LM → RM	None	NR
Liu et al [13]	2012	20	2.1 cm	Neg	SM + SNB	None	NR
Kshirsagar et al [11]	2006	82	NR	3/5 Pos	MRM + ALND	Radiotherapy	Recurrence at 2 years
Maciag et al [12]	2006	80	4 cm	1/10 Pos	LM → SM + ALND	Radiotherapy + endocrine therapy	Remain well after 5 years of follow-up
Miliauskas et al [10]	1991	13	3.8 cm	Neg	LM → ScM	None	Remain well after 30 months of follow-up
Hjorth et al [9]	1977	21	NR	Neg	SM	None	Remain well after 2 years of follow-up
Ferlito et al [8]	1974	60	NR	Neg	SM	None	NR
Verani et al [7]	1973	78	3.5 cm	Neg	MRM + ALND	None	Lung metastasis
Woyke et al [6]	1970	37	NR	Neg	LM	None	Recurrence at 5 and 7 years
Ferlito [5]	1969	Middle aged	NR	NR	NR	NR	NR

Table 1. Summary of Male Adenoid Cystic Carcinoma of Breast

References

Year

Age

Diameter

Node

Surgery

Adjuvant treatment

Outcome of follow up

Neg: negative; Pos: positive; NR: no report; LM: lumpectomy; MRM: modified radical mastectomy; ALND: axillary lymph node dissection; ScM: subcutaneous mastectomy; SM: simple mastectomy; SNB: sentinel node biopsy; RM: radical mastectomy.

Presenting case

2021

1.3 cm

Neg

LM → MRM + ALND

None

Remain well after 24 months of follow-up

Hogan and Fan [20]

2020

2.1 cm

Radiotherapy

Lung metastasis

Pang et al [19]

2019

1.2 cm

Neg

LM → MRM + ALND

Postoperative chemotherapy

Remain well after 26 months of follow-up

Douglas and Mackenzie [18]

2019

5.0 cm

Neg

ScM → SM + SNB

None

Remain well after 12 months of follow-up

Zadeh et al [17]

2017

4.0 cm

Neg

MRM + ALND

None

Remain well after 12 months of follow-up

Tang et al [16]

2015

3.0 cm

Neg

RM + ALND

Endocrine therapy

Remain well after 67 months of follow-up

Yoo et al [15]

2013

1.7 cm

Pos

None

Bone and lung metastasis

Sahan et al [14]

2012

1.3 cm

LM → RM

None

Liu et al [13]

2012

2.1 cm

Neg

SM + SNB

None

Kshirsagar et al [11]

2006

3/5 Pos

MRM + ALND

Radiotherapy

Recurrence at 2 years

Maciag et al [12]

2006

4 cm

1/10 Pos

LM → SM + ALND

Radiotherapy + endocrine therapy

Remain well after 5 years of follow-up

Miliauskas et al [10]

1991

3.8 cm

Neg

LM → ScM

None

Remain well after 30 months of follow-up

Hjorth et al [9]

1977

Neg

None

Remain well after 2 years of follow-up

Ferlito et al [8]

1974

Neg

None

Verani et al [7]

1973

3.5 cm

Neg

MRM + ALND

None

Lung metastasis

Woyke et al [6]

1970

Neg

None

Recurrence at 5 and 7 years

Ferlito [5]

1969

Middle aged